AMW GmbH Executes on Growth Strategy with Record Sales and Increased Earnings for 2025
Warngau, Germany, April 13, 2026
AMW GmbH, a specialty pharmaceutical company focused on biodegradable controlled-release drug delivery systems, today reported financial results for the year ended December 31, 2025. AMW GmbH reported consolidated revenues for the 2025 financial year of EUR 44.6 million, an increase of 17% compared to the previous year (2024: EUR 38.2 million) and therefore the fourth consecutive sales record for the Group. Furthermore, EBITDA once again increased in the reporting year, leading to operating profitability for the fourth year in succession. For the financial year 2026, sales are expected to grow again in the double-digit percentage range with correspondingly positive effects on EBITDA.
Increased sales figures of AMW’s implants goserelin and leuprorelin were the main drivers for the rise in revenues. In addition, AMW’s wholly owned subsidiary Endomedica GmbH contributed significantly to the overall revenues by achieving the fifth consecutive sales record in a row. Endomedica is responsible for marketing leuprorelin as Leugon® in Germany. Due to another rise in productivity, AMW GmbH has again been able to increase its production volume, resulting in increased sales figures and profitability. The Company plans to invest its earnings in the expansion of production capacities and its research and development activities in the area of biodegradable implants.
“Over the last 15 months, we achieved significant milestones to further drive AMW’s continued growth,” commented Philipp Karbach, CEO and shareholder of AMW GmbH. “At an operational level, we could once again report record sales for the financial year 2025, thanks to the tireless efforts of our employees, to whom I would like to express my sincere gratitude. From a financial standpoint, the Company’s equity position was considerably strengthened by positive net results for the reporting year, and the closing of a long-term financing agreement in mid-2025 ensures significantly reduced interest expenses in the future. Ultimately, our operational and financial achievements have been recognized by the investment community, leading to the recently announced changes in our shareholder structure, designed to support our long-term growth strategy.”
###
About AMW GmbH:
AMW GmbH is a specialty pharmaceutical company focused on biodegradable implants, providing patients and partners access to value-added medicines for improved adherence and cost-effective therapies. The Company covers the entire value chain, from (co-)development to manufacturing and international commercialization.
AMW GmbH has two approved pharmaceutical products: implants releasing goserelin or leuprorelin respectively, which are distributed worldwide via direct sales and out-licensing. In Germany, leuprorelin is marketed as Leugon® by AMW’s fully owned subsidiary Endomedica GmbH. Based on its unparalleled expertise in formulation development, the Company collaborates with pharma and biotech partners worldwide to develop and manufacture high-quality products and life-cycle solutions.
AMW GmbH is based in Warngau near Munich, Germany.
For further information, please contact: